Cargando…

New uses and formulations of glucagon for hypoglycaemia

Hypoglycaemia is the more frequent complication of insulin therapy and the main barrier to tight glycaemic control. Injectable glucagon and oral intake of carbohydrates are the recommended treatments for severe and non-severe hypoglycaemia episodes, respectively. Nasal glucagon is currently being de...

Descripción completa

Detalles Bibliográficos
Autores principales: Beato-Víbora, Pilar I, Arroyo-Díez, Francisco J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675539/
https://www.ncbi.nlm.nih.gov/pubmed/31402931
http://dx.doi.org/10.7573/dic.212599
_version_ 1783440639317245952
author Beato-Víbora, Pilar I
Arroyo-Díez, Francisco J
author_facet Beato-Víbora, Pilar I
Arroyo-Díez, Francisco J
author_sort Beato-Víbora, Pilar I
collection PubMed
description Hypoglycaemia is the more frequent complication of insulin therapy and the main barrier to tight glycaemic control. Injectable glucagon and oral intake of carbohydrates are the recommended treatments for severe and non-severe hypoglycaemia episodes, respectively. Nasal glucagon is currently being developed as a ready-to-use device, to simplify severe hypoglycaemia rescue. Stable forms of liquid glucagon could open the field for different approaches for mild to moderate hypoglycaemia treatment, such as mini-doses of glucagon or continuous subcutaneous glucagon infusion as a part of dual-hormone closed-loop systems. Pharmaceutical companies are developing stable forms of native glucagon or glucagon analogues for that purpose.
format Online
Article
Text
id pubmed-6675539
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioExcel Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-66755392019-08-09 New uses and formulations of glucagon for hypoglycaemia Beato-Víbora, Pilar I Arroyo-Díez, Francisco J Drugs Context Review Hypoglycaemia is the more frequent complication of insulin therapy and the main barrier to tight glycaemic control. Injectable glucagon and oral intake of carbohydrates are the recommended treatments for severe and non-severe hypoglycaemia episodes, respectively. Nasal glucagon is currently being developed as a ready-to-use device, to simplify severe hypoglycaemia rescue. Stable forms of liquid glucagon could open the field for different approaches for mild to moderate hypoglycaemia treatment, such as mini-doses of glucagon or continuous subcutaneous glucagon infusion as a part of dual-hormone closed-loop systems. Pharmaceutical companies are developing stable forms of native glucagon or glucagon analogues for that purpose. BioExcel Publishing Ltd 2019-07-30 /pmc/articles/PMC6675539/ /pubmed/31402931 http://dx.doi.org/10.7573/dic.212599 Text en Copyright © 2019 Beato-Víbora PI, Arroyo-Díez FJ. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.
spellingShingle Review
Beato-Víbora, Pilar I
Arroyo-Díez, Francisco J
New uses and formulations of glucagon for hypoglycaemia
title New uses and formulations of glucagon for hypoglycaemia
title_full New uses and formulations of glucagon for hypoglycaemia
title_fullStr New uses and formulations of glucagon for hypoglycaemia
title_full_unstemmed New uses and formulations of glucagon for hypoglycaemia
title_short New uses and formulations of glucagon for hypoglycaemia
title_sort new uses and formulations of glucagon for hypoglycaemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675539/
https://www.ncbi.nlm.nih.gov/pubmed/31402931
http://dx.doi.org/10.7573/dic.212599
work_keys_str_mv AT beatoviborapilari newusesandformulationsofglucagonforhypoglycaemia
AT arroyodiezfranciscoj newusesandformulationsofglucagonforhypoglycaemia